Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
(NASDAQ:ANAB), Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment period Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs Max response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients […]